Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

2026.01.11
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA, from December 6 to 9, 2025, bringing together the latest research advances and clinical progress in hematology worldwide. At this year’s meeting, Professor Wang Huafeng’s team from The First Affiliated Hospital, Zhejiang University School of Medicine had six studies accepted, including one oral presentation and five poster presentations, with one poster receiving the ASH Outstanding Abstract Award. These achievements highlight the growing international academic influence of Chinese researchers in the field of acute leukemia.
Breakthroughs by Chinese Investigators in the Treatment of Metastatic Urothelial Carcinoma

Breakthroughs by Chinese Investigators in the Treatment of Metastatic Urothelial Carcinoma

2026.01.10
At a recent academic conference on urologic oncology, Professor Jun Guo from Peking University Cancer Hospital & Institute delivered an important presentation systematically reviewing the ten-year journey of Chinese researchers in the field of drug therapy for urothelial carcinoma (UC)—from following international trends to taking a leading role. His lecture focused on the landmark achievements of China-originated antibody–drug conjugates (ADCs), represented by disitamab vedotin (RC48), particularly when combined with immunotherapy. Based on Professor Guo’s presentation, this article aims to showcase the international leap achieved by Chinese research in urologic oncology.
Professor Jingjing Wang Provides an In-Depth Analysis of Precision Strategies and PARP Inhibitor–Based Combinations in Prostate Cancer

Professor Jingjing Wang Provides an In-Depth Analysis of Precision Strategies and PARP Inhibitor–Based Combinations in Prostate Cancer

2026.01.10
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting convened leading experts in urologic oncology from across China to discuss cutting-edge diagnostic and therapeutic strategies for genitourinary malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer. During the conference, Professor Jingjing Wang, representing the field of medical oncology, delivered an outstanding presentation grounded in the latest evidence-based data, focusing on precision treatment strategies for metastatic castration-resistant prostate cancer (mCRPC), with particular emphasis on combination regimens involving PARP inhibitors. Based on Professor Wang’s presentation, this article systematically reviews the therapeutic challenges of mCRPC, genetic screening strategies, and the clinical benefits of emerging combination approaches, with the aim of providing practical insights for clinicians.
Professor Xiaolin Lu Offers an In-Depth Analysis of the BCG Dilemma and the Future of Novel Intravesical and Combination Immunotherapies

Professor Xiaolin Lu Offers an In-Depth Analysis of the BCG Dilemma and the Future of Novel Intravesical and Combination Immunotherapies

2026.01.10
Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urologic oncology from China and abroad. The meeting focused on bladder-sparing strategies for non–muscle-invasive bladder cancer (NMIBC), advances in novel intravesical agents, and the latest developments in immunotherapy. At the conference, Professor Xiaolin Lu from Fudan University Shanghai Cancer Center delivered a dedicated presentation from the perspective of intravesical therapy, systematically outlining the challenges in NMIBC management. He highlighted groundbreaking clinical trial results from the Fudan Cancer Center team on novel intravesical agents—particularly interleukin-15 (IL-15) and its fusion proteins, modified chemotherapeutic formulations, and oncolytic viruses—painting a new blueprint for the future treatment of NMIBC.
Professor Liang Aibin: Breaking Through Relapse and Resistance—Advancing Innovation in Dual-Target CAR-T Therapy | 2025 International Conference on Cell and Immunotherapy

Professor Liang Aibin: Breaking Through Relapse and Resistance—Advancing Innovation in Dual-Target CAR-T Therapy | 2025 International Conference on Cell and Immunotherapy

2026.01.08
To promote innovation in the fields of cell therapy and immunotherapy in China, facilitate in-depth discussion of key scientific challenges, and share the latest clinical research advances from a global perspective, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, China, from November 13–16, 2025. The meeting was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association, and co-hosted by The First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory.
Voice of China at ASH | Professor Chen Wenming: Bispecific Antibodies and Other Innovative Therapies Advance the Treatment of RRMM, While Mass Spectrometry Optimizes Response Assessment

Voice of China at ASH | Professor Chen Wenming: Bispecific Antibodies and Other Innovative Therapies Advance the Treatment of RRMM, While Mass Spectrometry Optimizes Response Assessment

2026.01.08
Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and poor prognosis, underscoring the urgent need for novel drugs and innovative therapeutic strategies. At the 2025 Annual Meeting of the American Society of Hematology (ASH), Professor Chen Wenming and his team from Beijing Chaoyang Hospital, Capital Medical University presented multiple innovative studies involving bispecific antibodies, the novel agent Eprenetapopt-like TRAIL agonist (Epnamin), and the application of mass spectrometry in minimal residual disease (MRD) monitoring.